177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy

Trial Details

NCT ID

NCT06449781

Phase

PHASE2

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Lutetium (177Lu) vipivotide tetraxetan

Locations (sample)

Gliwice, Poland|50.29761,18.67658

Key Eligibility Criteria

Giving a written informed consent
Histopathologically confirmed high or very high risk prostate cancer
Completion of radical locoregional treatment
Completion of locoregional treatment within 3 months before inclusion to the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →